Horizon Discovery Group plc Annual Report and Notice of Annual General Meeting (8696G)
02 June 2017 - 4:00PM
UK Regulatory
TIDMHZD
RNS Number : 8696G
Horizon Discovery Group plc
02 June 2017
HORIZON DISCOVERY GROUP PLC
("Horizon" or "the Company")
Annual Report and Notice of Annual General Meeting
Cambridge, UK, 2 June 2017: Horizon Discovery Group plc (LSE:
HZD) ("Horizon" or "the Company"), the world leader in the
application of gene editing technologies, announces that its annual
report and accounts for the year ended 31 December 2016, which
includes the notice convening the Company's 2017 Annual General
Meeting (AGM), has been posted to shareholders.
The annual report and accounts and 2017 notice of AGM are
available on the Investor Relations section of the Company's
website at www.horizondiscovery.com.
Horizon also announces that its 2017 AGM will be held on
Wednesday, 28 June 2017. The meeting will be held at the Company's
offices - Building 8100 Cambridge Research Park, Waterbeach,
Cambridge, CB25 9TL, commencing at 10.00am.
ENDS
For further information from Horizon Discovery Group plc, please
contact:
Horizon Discovery Group plc
Darrin Disley, Chief Executive Officer
Richard Vellacott, Chief Financial Officer
Chris Claxton, VP Investor Relations
Tel: +44 (0) 1223 655 580
Numis Securities Limited (Broker and NOMAD)
Michael Meade / Freddie Barnfield
Tel: +44 (0) 207 260 1000
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott / Susan Stuart / Matthew Neal / Melissa
Gardiner
Tel: +44 (0) 20 3709 5701
Email: horizon@consilium-comms.com
Zyme Communications (Trade and Regional Media)
Katie Odgaard
Tel: +44 (0)7787 502 947
Email: katie.odgaard@zymecommunications.com
About Horizon Discovery Group plc www.horizondiscovery.com
Horizon Discovery Group plc (LSE: HZD) ("Horizon"), is a
world-leading gene editing company that designs and engineers
genetically-modified cells and then applies them in research and
clinical applications that advance human health.
Horizon's core capabilities are built around its proprietary
translational genomics platform, a highly precise and flexible
suite of gene editing tools (rAAV, ZFN, CRISPR and Transposon) able
to alter almost any gene sequence in human or mammalian
cell-lines.
Horizon offers over 23,000 catalogue products and related
research services, almost all of which are based on the generation
and application of cell and animal models that accurately
recapitulate the disease-causing genetic anomalies found in
diseases like cancer. Horizon's commercial offering has been
adopted by over 1,600 unique research organisations in over 50
countries as well as in the Company's own R&D pipeline to
support a greater understanding of the genetic drivers of disease
and the development of molecular, cell and gene therapies that can
be prescribed on a personalised basis.
Horizon is headquartered in Cambridge, UK, and is listed on the
London Stock Exchange's AIM market under the ticker "HZD".
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAEKFELFXEFF
(END) Dow Jones Newswires
June 02, 2017 02:00 ET (06:00 GMT)
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From Apr 2024 to May 2024
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From May 2023 to May 2024